课题基金 / 基金详情

TRITIUM NMR ANALYSIS VT279 & VT286: CARDIOVASCULAR & PULMONARY DISEASE: SODIUM

TRITIUM NMR ANALYSIS VT279 & VT286: CARDIOVASCULAR & PULMONARY DISEASE: SODIUM
氚核磁共振分析 VT279
批准号：
6220438
负责人：
PHILIP G. WILLIAMS
金额：
$0.52万
依托单位：
UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-08-01 至 2000-07-31
来源：
https://reporter.nih.gov/project-details/6220438
关键词：
biological products biomedical resource

项目摘要

项目成果

PHILIP G. WILLIAMS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The subject compounds were tritium labelled under contract at Vitrax, Inc. As a small business, Vitrax, Inc. lacks the resources to conduct tritium NMR analyses of labelled products. Such NMR studies serve to confirm the site and level of tritium labelling, as a final step in the quality assurance for customers. VT279 is a new candidate sodium channel blocker. VT286 is a new drug candidate under evaluation for cardiovascular and pulmonary disease applications. Tritium and proton NMR analyses only. User Details: Experiment Details: User Number: 1703 NMR City, State: Placentia, CA 1 day Funding Source: Industry 2 compounds Charge: $458.62 Program Income: $458.62
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
THERMAL OXIDATION OF ORGANIC CHEMICALS USING CATALYTIC CHEMICAL OXIDATION
TRITIUM NMR ANALYSIS OF VT247: CARDIOVASCULAR & PULMONARY DISEASE
WORLD WIDE WEB SITE: DISSEMINATION & EDUCATION: TRITIUM LABELLING
TRITIUM NMR ANALYSIS VT279 & VT286: CARDIOVASCULAR & PULMONARY DISEASE: SODIUM
海外基金